NCT00049127 2019-10-21
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
Clinical Trials
8 trialsNCT00401024 2018-06-28
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00010049 2018-06-27
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00387933 2015-10-14
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Phase 1 Completed
NCT00354068 2013-03-28
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Duke University
Phase 1 Completed
NCT00613054 2012-12-05
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Duke University
Phase 1 Completed
NCT00039364 2012-07-24
Imatinib Mesylate in Treating Patients With Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00290771 2011-05-16
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Phase 2 Terminated